Year-end Sale % OFF 
Abstract
β-Galactosidase is closely related to primary ovarian cancer and highly expressed in metastatic ovarian cancer. Therefore, the development of effective tool for in situ detecting β-gal is urgently needed for further studies in ovarian cancer. Inspired by the advantages of near-infrared (NIR) fluorescence imaging, a NIR fluorescent probe (DCM-CHO-βgal) with improved near-infrared fluorescence emission and detection performance was reasonably designed for the quantification and visualization of β-gal, employing structurally modified dicyanobenzopyran derivative (DCM-CHO-OH) as fluorophore. DCM-CHO-βgal showed a rapid response (<20 min) towards β-gal accompanied by nearly 40-fold fluorescence enhancement at 665 nm. DCM-CHO-βgal can quantitatively detect β-gal ranging from 0.2 to 3 U/mL with a low detection limit (3.15 × 10−5 U/mL), and can selectively detect β-gal in the presence of other possible interferences. In view of excellent optical, analytical performance and good biocompatibility, DCM-CHO-βgal was applied to the visualization of endogenous β-gal in ovarian cancer cells and zebrafish, which provided a powerful tool for the in-depth study of the role of β-gal in β-gal-related diseases.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
